Racial Disparities in Cancer Guideline-Concordant Treatment Using Surveillance, Epidemiology, and End Results Data for Patients With NSCLC
Introduction: Despite efforts to achieve health care equality, racial/ethnic disparities persist in lung cancer survival in the United States, with non-Hispanic Black patients experiencing higher mortality compared with non-Hispanic Whites. Previous research often focused on single treatments, overl...
Saved in:
| Main Authors: | Eric Ababio Anyimadu, MS, Jacklyn M. Engelbart, MD, Jason Semprini, PhD, Amanda Kahl, MPH, Cameron Trentz, MS, John M. Buatti, MD, Thomas L. Casavant, PhD, Mary E. Charlton, PhD, Guadalupe Canahuate, PhD |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | JTO Clinical and Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364324001176 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Rural Patients’ Perceived Importance of Racial and Ethnic Concordance With Providers and Receipt of Annual Routine Visits
by: Bobbie L Johannes PhD, MPH, et al.
Published: (2025-05-01) -
Patient-Reported Outcomes From LIBRETTO-431: First-Line Selpercatinib Versus Chemotherapy With Pembrolizumab in RET Fusion-Positive NSCLC
by: Caicun Zhou, MD, PhD, et al.
Published: (2025-07-01) -
Post-discontinuation Survival in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Pooled Analysis of Prospective Cohort Studies
by: Yusuke Inoue, MD, PhD, et al.
Published: (2025-08-01) -
Phase 2 Trial of Combination Radiotherapy and Pembrolizumab Plus Chemotherapy in Patients With Previously Untreated Metastatic NSCLC: NJLCG 1902
by: Yoko Tsukita, MD, PhD, et al.
Published: (2025-05-01) -
Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50%
by: Yoshihito Kogure, MD, PhD, et al.
Published: (2025-03-01)